Safe and Highly Efficient Lipid-Pro-Dexamethasone Nanoparticles for mRNA Delivery and Base Editing
- 24 February 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (9) , 10225-10240
Abstract
The inherent immunogenicity of mRNA lipid nanoparticles (LNPs) poses a major challenge to their application in disease treatment. In this study, we developed a series of innovative dexamethasone (DEX) prodrug ionizable lipids (DPILs) to address the need for safe and effective mRNA delivery, leading to the establishment of the Safe and Highly Efficient Lipid-pro-dexamethasone (SHIELD) LNP platform. The lead formulation, DEX-SPM-CP10 SHIELD LNP, not only markedly decreased the levels of multiple proinflammatory cytokines but also achieved mRNA delivery efficiency comparable to that of the FDA-approved SM-102 LNP. Furthermore, the SHIELD platform demonstrated universality, as incorporating specific ratios of DPILs into various LNPs targeting different organs (such as the liver, lungs, spleen, and pancreas) led to notable reductions in inflammatory responses and enhancements in mRNA expression, highlighting its superiority over strategies that incorporate free DEX. Subsequently, we investigated its application in gene editing therapy by codelivering ABEmax mRNA and sgRNA to edit the EGFP reporter gene and endogenous PCSK9 gene, as well as in protein replacement therapy through multiple injections of mRNA-SHIELD LNPs. All of these results demonstrated excellent delivery efficacy with minimal immunogenicity, fully illustrating the therapeutic potential of this platform. Taken together, the SHIELD platform offers safe and efficient mRNA delivery and has the potential to expand the therapeutic applications of mRNA-based therapies.Keywords
Funding Information
- China Postdoctoral Science Foundation (2023M740101)
- National Basic Research Program of China (973 Program) (2024YFB3814800)
- Tianjin Key Science and Technology Project (24ZXZSSS00270)
- National Natural Science Foundation of China (NSFC) (32171386)
- National Natural Science Foundation of China (NSFC) (82272139)
- National Natural Science Foundation of China (NSFC) (U23A20488)
- Key Laboratory of Organ Regeneration and Reconstruction, Chinese Academy of Sciences (2024KF11)
- Open Competition to Select the Best Candidates (NCTIB2023XB02001)
This publication has 54 references indexed in Scilit:
- Simplified Lipid Nanoparticles for Tissue‐ And Cell‐Targeted mRNA Delivery Facilitate Precision Tumor Therapy in a Lung Metastasis Mouse ModelAdvanced Materials, 2024
- Development of Organ Targeting Lipid Nanoparticles with Low Immunogenicity and Their Application in the Treatment of Pulmonary FibrosisAngewandte Chemie International Edition, 2024
- Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying lengthJournal of Biomedical Materials Research Part A, 2024
- Physicochemical Targeting of Lipid Nanoparticles to the Lungs Induces Clotting: Mechanisms and SolutionsAdvanced Materials, 2024
- Cellular Trafficking of Nanotechnology‐Mediated mRNA DeliveryAdvanced Materials, 2023
- Lipid Nanoparticles Optimized for Targeting and Release of Nucleic AcidAdvanced Materials, 2023
- Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer TherapyAdvanced Materials, 2023
- Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection PotencyAdvanced Materials, 2023
- Rational design of anti‐inflammatory lipid nanoparticles for mRNA deliveryJournal of Biomedical Materials Research Part A, 2022
- Dendrimer‐Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type IAdvanced Materials, 2018